Ogkologos

4396 ΔΗΜΟΣΙΕΥΣΕΙΣ 0 ΣΧΟΛΙΑ

Additional 5 Years of AI Treatment Reduces Distant Recurrence Rates Among...

Ogkologos - 25 Αυγούστου, 2025

FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma

Ogkologos - 22 Αυγούστου, 2025

Clinical Benefit and Genomic Features Associations Observed with Pembrolizumab Plus Axitinib...

Ogkologos - 21 Αυγούστου, 2025

Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated...

Ogkologos - 20 Αυγούστου, 2025

No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in...

Ogkologos - 19 Αυγούστου, 2025

EMA Recommends Granting a Marketing Authorisation for Belantamab Mafodotin

Ogkologos - 18 Αυγούστου, 2025

ESMO Joins the European Health Alliance on Alcohol (EHAA) Seeking to...

Ogkologos - 14 Αυγούστου, 2025

CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated...

Ogkologos - 14 Αυγούστου, 2025

FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma

Ogkologos - 14 Αυγούστου, 2025

EMA Recommends Granting a Marketing Authorisation for Vorasidenib

Ogkologos - 13 Αυγούστου, 2025

1...414243...440 Σελίδα 42 από 440

MOST POPULAR

EMA Recommends Granting a Marketing Authorisation for Piflufolastat (18F)

1 Ιουνίου, 2023

ESMO Sarcoma and Rare Cancers Congress 2025, Lugano, Switzerland, 20-22 March

14 Μαρτίου, 2025

Por qué la Reunión Anual de la American Society of Clinical...

1 Ιουνίου, 2021

Better together: improving brain tumour treatment

13 Φεβρουαρίου, 2023

Φόρτωση περισσοτέρων

Additional 5 Years of AI Treatment Reduces Distant Recurrence Rates Among...

FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma

Clinical Benefit and Genomic Features Associations Observed with Pembrolizumab Plus Axitinib...

Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated...

No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in...

EMA Recommends Granting a Marketing Authorisation for Belantamab Mafodotin

ESMO Joins the European Health Alliance on Alcohol (EHAA) Seeking to...

CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated...

FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma

EMA Recommends Granting a Marketing Authorisation for Vorasidenib

MOST POPULAR

EMA Recommends Granting a Marketing Authorisation for Piflufolastat (18F)

ESMO Sarcoma and Rare Cancers Congress 2025, Lugano, Switzerland, 20-22 March

Por qué la Reunión Anual de la American Society of Clinical...

Better together: improving brain tumour treatment

HOT NEWS

Take a Small Step

Managing Cancer Pain: Are Better Approaches on the Horizon?

Cholesterol Drug May Help Protect the Heart during Chemotherapy for Lymphoma

Stem cell research: meet the scientist growing ‘mini guts’ in her...

ΔΗΜΟΦΙΛΕΊΣ ΘΈΣΕΙΣ

ΚΑΡΚΙΝΟΣ ΘΥΜΟΥ ΑΔΕΝΑ (ΘΥΜΩΜΑ)

ΣΤΑΤΙΣΤΙΚΑ

ΚΕΝΤΡΙΚΟΥ ΝΕΥΡΙΚΟΥ ΣΥΣΤΗΜΑΤΟΣ

ΔΗΜΟΦΙΛΗ ΚΑΤΗΓΟΡΙΑ